ImmunoCellular Therapeutics Debt

IMUCDelisted Stock  USD 0.47  0.00  0.00%   
ImmunoCellular Therapeutics holds a debt-to-equity ratio of 0.39. With a high degree of financial leverage come high-interest payments, which usually reduce ImmunoCellular Therapeutics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

ImmunoCellular Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. ImmunoCellular Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps ImmunoCellular Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect ImmunoCellular Therapeutics' stakeholders.
For most companies, including ImmunoCellular Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for ImmunoCellular Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, ImmunoCellular Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that ImmunoCellular Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which ImmunoCellular Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of ImmunoCellular Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, ImmunoCellular Therapeutics is said to be less leveraged. If creditors hold a majority of ImmunoCellular Therapeutics' assets, the Company is said to be highly leveraged.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

ImmunoCellular Therapeutics Debt to Cash Allocation

ImmunoCellular Therapeutics currently holds 2.78 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. ImmunoCellular Therapeutics has a current ratio of 1.48, which is within standard range for the sector. Debt can assist ImmunoCellular Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunoCellular Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunoCellular Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunoCellular to invest in growth at high rates of return. When we think about ImmunoCellular Therapeutics' use of debt, we should always consider it together with cash and equity.

ImmunoCellular Therapeutics Assets Financed by Debt

Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ImmunoCellular Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ImmunoCellular Therapeutics, which in turn will lower the firm's financial flexibility.

ImmunoCellular Therapeutics Corporate Bonds Issued

Most ImmunoCellular bonds can be classified according to their maturity, which is the date when ImmunoCellular Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understaning ImmunoCellular Therapeutics Use of Financial Leverage

ImmunoCellular Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures ImmunoCellular Therapeutics' total debt position, including all outstanding debt obligations, and compares it with ImmunoCellular Therapeutics' equity. Financial leverage can amplify the potential profits to ImmunoCellular Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if ImmunoCellular Therapeutics is unable to cover its debt costs.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in ImmunoCellular Pink Sheet

If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.